Peptide microarrays coupled to machine learning reveal individual epitopes from human antibody responses with neutralizing capabilities against SARS-CoV-2

ABSTRACT The coronavirus SARS-CoV-2 is the causative agent for the disease COVID-19. To capture the IgA, IgG, and IgM antibody response of patients infected with SARS-CoV-2 at individual epitope resolution, we constructed planar microarrays of 648 overlapping peptides that cover the four major structural proteins S(pike), N(ucleocapsid), M(embrane), and E(nvelope). The arrays were incubated with sera of 67 SARS-CoV-2 positive and 22 negative control samples. Specific responses to SARS-CoV-2 were detectable, and nine peptides were associated with a more severe course of the disease. A random forest model disclosed that antibody binding to 21 peptides, mostly localized in the S protein, was associated with higher neutralization values in cellular anti-SARS-CoV-2 assays. For antibodies addressing the N-terminus of M, or peptides close to the fusion region of S, protective effects were proven by antibody depletion and neutralization assays. The study pinpoints unusual viral binding epitopes that might be suited as vaccine candidates.

[1]  Bradley J. Wheeler,et al.  Multiplex assessment of SARS-CoV-2 antibodies improves assay sensitivity and correlation with neutralizing antibodies , 2021, Clinical Biochemistry.

[2]  S. Boyd,et al.  Antibody and B cell responses to SARS-CoV-2 infection and vaccination , 2021, Cell Host & Microbe.

[3]  D. O’Connor,et al.  The landscape of antibody binding in SARS-CoV-2 infection , 2021, PLoS biology.

[4]  William T. Harvey,et al.  SARS-CoV-2 variants, spike mutations and immune escape , 2021, Nature Reviews Microbiology.

[5]  N. Weiss,et al.  Author Correction: Rapid decline of neutralizing antibodies against SARS-CoV-2 among infected healthcare workers , 2021, Nature Communications.

[6]  M. Gavrović-Jankulović,et al.  IgM and IgG Immunoreactivity of SARS-CoV-2 Recombinant M Protein , 2021, International journal of molecular sciences.

[7]  M. Addo,et al.  Longitudinal Development of Antibody Responses in COVID-19 Patients of Different Severity with ELISA, Peptide, and Glycan Arrays: An Immunological Case Series , 2021, Pathogens.

[8]  M. Müller,et al.  SARS-CoV-2 Proteome-Wide Analysis Revealed Significant Epitope Signatures in COVID-19 Patients , 2021, Frontiers in Immunology.

[9]  S. Fukumoto,et al.  SARS-CoV-2-induced humoral immunity through B cell epitope analysis in COVID-19 infected individuals , 2021, Scientific Reports.

[10]  H. Rammensee,et al.  Exploring beyond clinical routine SARS-CoV-2 serology using MultiCoV-Ab to evaluate endemic coronavirus cross-reactivity , 2021, Nature Communications.

[11]  R. Pinapati,et al.  Immunoreactive peptide maps of SARS-CoV-2 , 2021, Communications biology.

[12]  V. Calvez,et al.  Rapid decline of neutralizing antibodies against SARS-CoV-2 among infected healthcare workers , 2021, Nature Communications.

[13]  J. Gunst,et al.  SARS-CoV-2 persistence is associated with antigen-specific CD8 T-cell responses , 2021, EBioMedicine.

[14]  K. Schnatbaum,et al.  Peptide microarray‐based analysis of antibody responses to SARS‐CoV‐2 identifies unique epitopes with potential for diagnostic test development , 2020, medRxiv.

[15]  Zane W. Fink,et al.  Epitope-resolved profiling of the SARS-CoV-2 antibody response identifies cross-reactivity with endemic human coronaviruses , 2020, Cell Reports Medicine.

[16]  C. Dahlke,et al.  Rapid Response to Pandemic Threats: Immunogenic Epitope Detection of Pandemic Pathogens for Diagnostics and Vaccine Development Using Peptide Microarrays , 2020, Journal of proteome research.

[17]  Jeremy L. Praissman,et al.  Virus-Receptor Interactions of Glycosylated SARS-CoV-2 Spike and Human ACE2 Receptor , 2020, Cell Host and Microbe.

[18]  Dong Men,et al.  SARS-CoV-2 proteome microarray for global profiling of COVID-19 specific IgG and IgM responses , 2020, Nature Communications.

[19]  Devy M. Emperador,et al.  Antibody tests for identification of current and past infection with SARS‐CoV‐2 , 2020, The Cochrane database of systematic reviews.

[20]  Y. Li,et al.  Linear epitopes of SARS-CoV-2 spike protein elicit neutralizing antibodies in COVID-19 patients , 2020, Cellular & Molecular Immunology.

[21]  C. Poh,et al.  Two linear epitopes on the SARS-CoV-2 spike protein that elicit neutralising antibodies in COVID-19 patients , 2020, Nature Communications.

[22]  J. Greenbaum,et al.  Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals , 2020, Cell.

[23]  Shufeng Liu,et al.  Effective Heat Inactivation of SARS-CoV-2 , 2020, medRxiv.

[24]  P. Bagos,et al.  Antibody Tests in Detecting SARS-CoV-2 Infection: A Meta-Analysis , 2020, medRxiv.

[25]  Xiaobo Yu,et al.  SARS-CoV-2 Proteome Microarray for Mapping COVID-19 Antibody Interactions at Amino Acid Resolution , 2020, bioRxiv.

[26]  A. Abd El Wahed,et al.  Serological Analysis of Herpes B Virus at Individual Epitope Resolution: From Two dimensional Peptide Arrays to Multiplex Bead Flow Assays. , 2019, Analytical chemistry.

[27]  Lindsey C. Szymczak,et al.  Peptide Arrays: Development and Application. , 2018, Analytical chemistry.

[28]  Bjoern Peters,et al.  BepiPred-2.0: improving sequence-based B-cell epitope prediction using conformational epitopes , 2017, Nucleic Acids Res..

[29]  R. Desrosiers,et al.  Evidence against Extracellular Exposure of a Highly Immunogenic Region in the C-Terminal Domain of the Simian Immunodeficiency Virus gp41 Transmembrane Protein , 2011, Journal of Virology.

[30]  R. Frank,et al.  SC2: A novel process for manufacturing multipurpose high-density chemical microarrays , 2006 .

[31]  Conrad C. Huang,et al.  UCSF Chimera—A visualization system for exploratory research and analysis , 2004, J. Comput. Chem..

[32]  P. Talbot,et al.  Acute and Persistent Infection of Human Neural Cell Lines by Human Coronavirus OC43 , 1999, Journal of Virology.

[33]  R. Frank Spot-synthesis: an easy technique for the positionally addressable, parallel chemical synthesis on a membrane support , 1992 .